Optimal dosing of a platelet glycoprotein (GP) IIb/IIIa antagonist, lamifiban, using renal-based algorithms, in patients with acute coronary syndromes (ACS): Results from the PARAGON B study

Authors
Harrington, RA
Citation
Ra. Harrington, Optimal dosing of a platelet glycoprotein (GP) IIb/IIIa antagonist, lamifiban, using renal-based algorithms, in patients with acute coronary syndromes (ACS): Results from the PARAGON B study, J AM COL C, 36(1), 2000, pp. 319-319
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Journal title
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
ISSN journal
07351097 → ACNP
Volume
36
Issue
1
Year of publication
2000
Pages
319 - 319
Database
ISI
SICI code
0735-1097(200007)36:1<319:ODOAPG>2.0.ZU;2-4